{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eperezolid is an antibiotic agent developed for the treatment of a wide range of bacterial infections. The drug exerts its action by binding to 50 S ribosome subunit causing the inhibition of protein synthesis in bacterias. Eperezolid was tested in preclinical in vivo models of different becterial diseases in which it was shown to be active.
Status:
Investigational
Source:
NCT00401947: Phase 2 Interventional Terminated HCV Infection
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Erbulozole (R 55104) is a water soluble congener of the microtubule inhibitor tubulozole, which has proven to possess anti-invasive, antitumoral and radiosensitizing capacities. Erbulozole development for the treatment of cancer has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Trifenagrel is a potent inhibitor of arachidonate (AA)- and collagen-induced aggregation of platelets from several animal species and humans. When trifenagrel was administered p.o. to guinea pigs, there was a sustained (greater than 3 hr) inhibition of AA- and collagen-induced platelet aggregation ex vivo. In humans, trifenagrel inhibited the second phase of ADP-induced aggregation ex vivo up to 6 hr after a single dose of 100 to 300 mg p.o. The mechanism of action of trifenagrel appears to be a reversible inhibition of platelet AA cyclooxygenase. Although trifenagrel caused gastrointestinal irritation in dogs and humans, the nature of the damage suggests that the compound may have acted as a local irritant in these species. Furthermore, compared to aspirin trifenagrel produced significantly less gastric irritation and fecal blood loss in humans. Trifenagrel was developed for the treatment of ischemic heart disorders. However, this development was discontinued.
Status:
Investigational
Source:
INN:ramifenazone [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ramifenazone is pyrazolone derivative with analgesic, antipyretic, and anti-inflammatory activity. In preclinical studies, Ramifenazone shows potent inhibition of prostaglandin production, carrageenan edema, and yeast fever.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Gemopatrilat is a vasopeptidase inhibitor, that was found to inhibit plasma and renal angiotensin converting enzyme (ACE), as well as renal neutral endopeptidase (NEP). Gemopatrilat is rapidly absorbed, and causes inhibition of circulating and renal ACE and renal NEP after a single oral dose for up to 48 hours in rats. Potentially, this is because the free sulfhydryl group of gemopatrilat forms reversible disulfide linkages with plasma and tissue proteins and is thus eliminated from the body at a very slow rate. Similar metabolism of the compound was found in rat, dog, and human. Gemopatrilat was evaluated for its potential in treatment of antihypertensive activity in hypertension (independent of age, renin and salt status or ethnic origin), as well as its potential as a new therapeutic modality for the treatment of congestive heart failure. The drug was never marketed. A phase II study for treatment of hypertension and heart failure has been discontinued.
Status:
Investigational
Source:
NCT00126893: Phase 1 Interventional Terminated Myeloid Leukemia
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
CC-401 is a potent inhibitor of all three forms of c-Jun N-terminal Kinase (JNK) (Ki of 25 to 50 nM) and has at least 40-fold selectivity for JNK compared with other related kinases. Celgene was developing CC 401 for the treatment of cancer and inflammatory disorders. CC 401 was being developed in an IV formulation and was in a phase I trial in patients with refractory acute myelogenous leukaemia. However, trials have ended and the company is not pursuing CC 401, but will advance other JNK inhibitors.
Status:
Investigational
Source:
NCT00275197: Phase 2 Interventional Completed Depressive Disorder, Major
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Elzasonan (CP 448187) is a serotonin 1B/1D receptor antagonist. Elzasonan was primarily metabolized via oxidative N‐demethylation, N‐oxidation, and aryl hydroxylation. Pfizer was developing elzasonan for the treatment of anxiety and affective disorders however development has been discontinued.
Status:
Investigational
Source:
INN:tryparsamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tryparsamide is an arsenic compound with activity against Spirochaetes bacteria. Tryparsamide is used in the treatment of syphilis and African sleeping sickness. For decades Tryparsamide remained the standard treatment for trypanosomiasis. Tryparsamide has two remarkable properties: first, it increases the resistance of the individual by improving his general physical status; and, second, the high penetrability for nervous tissue which it possesses may increase the potential spirocheticidal action of the drug.
Status:
Investigational
Source:
USAN:NIFLURIDIDE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifluridide, an experimental insecticide, is used for the control of sucking and biting insects such as Phthiraptera. Nifluridide was systemically active against Triatoma infestans on mice and Rhodnius prolixus on cattle.
